当前位置：
X-MOL 学术
›
J. Pept. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Landscape and progress of global peptide drugs in obstetrics and gynaecology
Journal of Peptide Science ( IF 1.8 ) Pub Date : 2022-07-08 , DOI: 10.1002/psc.3443 Mi Tang 1, 2 , Jiang-Hui Cai 3 , Er-Dan Luo 2 , Hao-Yang Diao 2 , Yan Huang 2 , Li-Ling Xiong 4 , Sha Sha Xing 2 , Xiao Yang 4
Journal of Peptide Science ( IF 1.8 ) Pub Date : 2022-07-08 , DOI: 10.1002/psc.3443 Mi Tang 1, 2 , Jiang-Hui Cai 3 , Er-Dan Luo 2 , Hao-Yang Diao 2 , Yan Huang 2 , Li-Ling Xiong 4 , Sha Sha Xing 2 , Xiao Yang 4
Affiliation
|
Peptides have gained popularity in the global market during recent years and have been placed between small molecule drugs and biologics. However, little is known about the comprehensive landscape of peptide drugs in obstetrics and gynaecology. Herein, we analysed new peptide drug-related clinical trials in obstetrics and gynaecology registered on ClinicalTrials.gov. The number and percentage were used for statistical analysis, and a time trend analysis was conducted by calculating the annual growth rate. We aimed to provide the first overview of the changing landscape and status of global peptide drugs in this prospective field, including exploring drug targets, the cutting-edge oncotherapy of peptide vaccines and peptide–drug conjugates, and unsolved challenges with oral administration.
中文翻译：
全球肽类药物在妇产科领域的格局与进展
近年来，肽在全球市场上获得了普及，并被置于小分子药物和生物制剂之间。然而，人们对妇产科多肽药物的综合前景知之甚少。在此，我们分析了在 ClinicalTrials.gov 上注册的妇产科新肽药物相关临床试验。采用数量和百分比进行统计分析，通过计算年增长率进行时间趋势分析。我们旨在首次概述全球多肽药物在这一前瞻性领域中不断变化的格局和现状，包括探索药物靶点、多肽疫苗和多肽-药物偶联物的前沿肿瘤疗法，以及口服给药尚未解决的挑战。
更新日期：2022-07-08
中文翻译：
全球肽类药物在妇产科领域的格局与进展
近年来，肽在全球市场上获得了普及，并被置于小分子药物和生物制剂之间。然而，人们对妇产科多肽药物的综合前景知之甚少。在此，我们分析了在 ClinicalTrials.gov 上注册的妇产科新肽药物相关临床试验。采用数量和百分比进行统计分析，通过计算年增长率进行时间趋势分析。我们旨在首次概述全球多肽药物在这一前瞻性领域中不断变化的格局和现状，包括探索药物靶点、多肽疫苗和多肽-药物偶联物的前沿肿瘤疗法，以及口服给药尚未解决的挑战。
京公网安备 11010802027423号